R

Rhythm Pharmaceuticals
D

RYTM

55.650
USD
-0.42
(-0.75%)
Market Open
Volume
5,970
EPS
-4
Div Yield
-
P/E
-13
Market Cap
3,420,085,890
OverviewSignalsIdeasNews
Related Instruments
    A
    ARWR
    0.060
    (0.31%)
    19.510 USD
    C
    CRBP
    -0.070
    (-0.54%)
    12.890 USD
    C
    CRSP
    -0.470
    (-1.15%)
    40.250 USD
    E
    EDIT
    -0.05500
    (-4.17%)
    1.26500 USD
    N
    NTLA
    -0.130
    (-1.07%)
    12.060 USD
    P
    PRQR
    -0.02500
    (-0.95%)
    2.62000 USD
    Q
    QURE
    0.240
    (1.41%)
    17.290 USD
    R
    RARE
    -0.920
    (-2.08%)
    43.270 USD
    S
    SGMO
    -0.01000
    (-0.40%)
    2.48000 USD
    V
    VYGR
    -0.08000
    (-1.39%)
    5.68000 USD
    More
News

Title: Rhythm Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.